Organization
7 Interestana reports mention STAT+, newest first. Each is summarised from the original reporting and links back to its publisher.
The BIO 2026 international conference in San Diego featured discussions on the growing influence of China in drug development and strategies to bolster the U.S. biotech industry. Executives expressed concerns about Washington's political landscape and pricing policies, while also emphasizing…
STAT+ reported on significant AI developments discussed at a biotech conference in San Diego this week. The newsletter, a subscriber-exclusive guide to artificial intelligence in health care and medicine, highlighted a "crazy story" that executive editor Rick Berke shared…
STAT+ reported that pharmaceutical companies are actively engaging in mergers and acquisitions within the biotechnology sector, signaling a resurgence in biotech M&A activity. This trend is underscored by significant deals and a general increase in acquisition interest.
Pharmaceutical companies have significantly increased their acquisition activity, completing 32 biotech acquisitions valued at $1 billion or more in the past six months. This surge in deal-making has resulted in approximately $123 billion being spent by pharmaceutical and large biotech…
STAT+ published an article this week examining the efficacy of wearable devices for individuals with cardiovascular disease. The piece delves into whether these devices, which track metrics like heart rate, blood pressure, and activity levels, genuinely contribute to improved health…
STAT+ reported on a biotechnology company that leveraged an artificial intelligence model to re-evaluate a failed clinical trial, leading to new insights. The company, whose name was not explicitly stated in the provided text, utilized AI to analyze extensive datasets…
Verge Labs released STAT+ on an AI model named STAT+ designed to address patient stratification challenges in neurology clinical trials on an unspecified date. Verge Labs, co-founded by Alice Zhang over a decade ago, aimed to develop drugs for neurodegenerative…